BeStock  
Stocks › Biotechnology › PVLA

Palvella Therapeutics PVLA

US equityMarket cap rank #2653Biotechnology
$142.85 −$2.92 (-2.00%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $142.85 0.00%
Open$143.10
Prev close$145.77
Day range$142.22 – $148.69
Volume192.7K
Market cap$2.09B
P/E (TTM)–
Dividend yield–

PVLA Stock News

Headlines matching Palvella Therapeutics or the PVLA ticker, most recent first.

  • Chardan Capital Initiates Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $240Market news · 21 Sep 2026 · Direct mention
  • Palvella Therapeutics(PVLA.US) Director Sells US$4.17 Million in Common StockMarket news · 16 Sep 2026 · Direct mention
  • Form 144 | Palvella Therapeutics(PVLA.US) Director Proposes to Sell 4.14 Million in Common StocksMarket news · 12 Sep 2026 · Direct mention
  • Mizuho Securities Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $240Market news · 10 Sep 2026 · Direct mention
  • H.C. Wainwright Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $270Market news · 6 Aug 2026 · Direct mention
  • Truist Financial Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $207Market news · 5 Aug 2026 · Direct mention
  • A Quick Look at Today's Ratings for Palvella Therapeutics(PVLA.US), With a Forecast Between $207 to $267Market news · 5 Aug 2026 · Direct mention
  • Oppenheimer Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $210Market news · 5 Aug 2026 · Direct mention
  • LifeSci Capital Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $225Market news · 22 Jul 2026 · Direct mention
  • BTIG Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $215Market news · 22 Jul 2026 · Direct mention
  • TD Cowen Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Raises Target Price to $267 PositiveMarket news · 22 Jul 2026 · Direct mention
  • Analysts' Opinions Are Mixed on These Healthcare Stocks: Bio-Techne (TECH), Concentra Group Holdings Parent, Inc. (CON) and Palvella Therapeutics (PVLA)TipRanks · 1 Jul 2026 · Direct mention
  • CCORF Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $227Market news · 25 Jun 2026 · Direct mention
  • Stifel Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Maintains Target Price $250Market news · 24 Jun 2026 · Direct mention
  • Craig-Hallum Maintains Palvella Therapeutics(PVLA.US) With Buy Rating, Announces Target Price $205Market news · 22 Jun 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on PVLA.

Sign in to join the discussion.

Scroll to Top